Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Investor Presentation (January 2024)
26 slides from Xbrane Biopharma AB's investor presentation, January 2024
Slide 1: Xbrane – a World-Leading Biosimilar Developer
STO: XBRANE January 2024 Xbrane – a World-Leading Biosimilar Developer 1
Slide 2: Important information
Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in
Slide 3: Xbrane addresses global health challenges by developing affordable biosimilars
Xbrane addresses global health challenges by developing affordable biosimilars Core competence Differentiation Develop biosimilars from Patented platform technology for cell line to market approval and lowest production cost partner for sales and marketing Our purpose: Mid-term strategic focus “Enab
Slide 4: Xbrane – a world-leading biosimilar developer
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 27bn in originator sales
Slide 5: Biosimilars are follow-on products to biologics launched post patent expiry
Biosimilars are follow-on products to biologics launched post patent expiry Pharmaceuticals Small Molecules Biologics → 60% of global market, 1-3% p.a. growth1 → 40% of global market, 10-15% p.a. growth2 → Produced via chemical synthesis → Produced via recombinant DNA technology → Followed on by ide
Slide 6: Biosimilar development – faster, cost-effective & low risk
Biosimilar development – faster, cost-effective & low risk Pre-clinical Phase I Phase III Biosimilar Likelihood of Approval1 78% 95% development process Development time Capital requirement Prob. of success Cost effectiveness 7 years +€100 million MEDIUM - HIGH Improved patient access Discovery & De
Slide 7: Biosimilars rapidly claim majority of reference product market share
Biosimilars rapidly claim majority of reference product market share Rapid biosimilars uptake leading to USD 11.5bn in global sales (2021) Favorable margins & price discounts Branded products WW annual sales Biosimilars WW annual sales → Biosimilars have in recent launches taken +70% USD million USD
Slide 8: Biosimilar market expected to grow to USD 74bn by 2030
Biosimilar market expected to grow to USD 74bn by 2030 Biologics with >USD 260bn in sales lose exclusivity by 2032 Biosimilar market to grow by 17% per year through to 2030 Estimated cumulative global annual peak sales, USD billion Global biosimilar sales, USD billion 74.0 61.5 54.5 51.6 35.4 32.9 1
Slide 9: Xbrane – a world-leading biosimilar developer
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 27bn in originator sales 9
Slide 10: Xbrane´s modular platform technology enables significant yield advantage
Xbrane´s modular platform technology enables significant yield advantage Proprietary host cell line library Productivity enhancing technologies Process and analytical methods + + → Library of proprietary genetically → Productivity and quality enhancing → Specific production process methods engineere
Slide 11: Diverse development portfolio addressing a €27bn market
Diverse development portfolio addressing a €27bn market Originator peak sales estimate 2026* (€ billion) Biosimilar Ximluci® BIIB801™ Xdivane™ Xdarzane™ Current portfolio candidate Branded biologics Therapeutic Ophthalmology Immunology Oncology Oncology area 2020 (US) 2024 (US) 2029 (US) 2029 (US) P
Slide 12: World-leading partnerships secured with >€80m in upcoming milestones
World-leading partnerships secured with >€80m in upcoming milestones Product Ximluci® BIIB801TM Commercial Partner Territory Global ex. China Global Type Co-development License Upfront €7.5m USD 8m > €80m (pending) Milestones / Cost coverage €40-50m USD 80m Royalties/ profit sharing 50% EBITDA profi
Slide 13: Xbrane – a world-leading biosimilar developer
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 27bn in originator sales 13
Slide 14: Ximluci® – addressing a global underserved market
Ximluci® – addressing a global underserved market Lucentis® used in treatment of severe eye diseases Global unmet medical need due to high drug cost 5 million affected eyes Europe & US, 50% treated Affected vision Normal vision Untreated Lucentis Eylea Avastin 0.6 2.5 2.5 1.1 0.8 13 million affected
Slide 15: Ximluci® development update – FDA BsUFA date in April 2024
Ximluci® development update – FDA BsUFA date in April 2024 2022 2023 2024 Regulatory process EU Production launch volume* Regulatory process US Drug substance process scale-up Pre-filled syringe development June 2023 April 2024 H2 2024 Q1 2025 Feb 2022 July 2022 March 2023 Q2 2024 FDA accepts Expect
Slide 16: Ximluci® Launched across 12 European Markets
Ximluci® Launched across 12 European Markets European countries where Ximluci is launched (Q3 2023) Comments → Ximluci® launched across 12 countries in Europe → Planned launch in further countries during 2024 → Ophthalmology market is biosimilar-naïve, presenting opportunity to convert via prescribe
Slide 17: Ximluci® Launched across 35-40% of €5 billion ex-US market
Ximluci® Launched across 35-40% of € 5 billion ex-US market Retinal anti-VEGF sales (ex US) Comments € million Approx. € 200-300m / quarter additional 1400 market from off label Avastin1 → Ex-US market for retinal anti-VEGFs approx. € 5 billion annually 1200 → Markets where Ximluci ® is launched cov
Slide 18: Ximluci® – US Regulatory and Market update
Ximluci® – US Regulatory and Market update Retinal anti-VEGF sales (US) Commentary on Q3 2023 USD million Approx. USD 150m / quarter additional 2500 annual market from off label Avastin1 → Handful of interested parties with ongoing active negotiations for North America license 2000 → Mid-cycle revie
Slide 19: Xbrane – a world-leading biosimilar developer
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 27bn in originator sales 19
Slide 20: Cimzia® is a differentiated €2.1 billion TNFa inhibitor
Cimzia® is a differentiated €2.1 billion TNFa inhibitor Cimzia® is a differentiated TNFa inhibitor Cimzia® generated €1.8 billion in sales 2021 Cimzia® sales (€ millions) Rheumatoid Arthritis (RA) Psoriasis 2500 2000 1500 1000 500 → Cimzia® is a TNFa inhibitor that reduce immune response in auto-imm
Slide 21: BIIB801™ – the only publicly known Cimzia® biosimilar under development
BIIB801™ – the only publicly known Cimzia® biosimilar under development BIIB801™ programme Partnership with Biogen with attractive terms → Out-licensing of global rights → Pilot scale process established → Xbrane responsible for and fund pre-clinical → Ongoing tech-transfer/scale-up to selected drug
Slide 22: Well-positioned & commercially attractive oncology biosimilar portfolio
Well-positioned & commercially attractive oncology biosimilar portfolio Opportunity to make a difference Oncology biosimilar portfolio €48 billion of annual reference product sales Combined annual expected peak → Annual per patient cost of reference product sales Originator >USD 100K € billion 2028
Slide 23: Upcoming key milestones
Upcoming key milestones H1 2024: Ximluci® out-licensing of North American rights H1 2024: Ximluci® FDA approval H1 2024: XdivaneTM out-licensing Q3 2024: BIIB801 milestone payments contingent upon successful scale-up H2 2024: Ximluci® US launch Q1 2025: Reaching positive operating cash-f
Slide 24: Appendix
Xbrane – a world-leading biosimilar developer Appendix 24
Slide 25: Experienced management team and board
Experienced management team and board Management Board of Directors Martin Åmark Siavash Bashiri David Vikström Anders Wallström Anders Tullgren Eva Nilsagård Karin Wingstrand Mats Thorén CEO COO & Head of CTO Head of Manufacturing Chairman of the Director of the Director of the Director of the Bios
Slide 26: Latest financials & shareholder list
Latest financials & shareholder list Shareholder list (December 2023) Financial highlights Investor Name Shares Ownership, % SEK thousands Jan. – Sep. 2023 Jan. – Sep. 2022 Ashkan Pouya 3,270,298 10.97 Bengt Göran Westman 2,448,379 8.21 Revenue 171,835 40,305 STADA Arzneimittel AG 1,570,989 5.27 Ava
Xbrane Biopharma — Investor Presentation (January 2024) on 6ix